THE Therapeutic Goods Administration has confirmed the registration of Gilead Sciences Australia's Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C infection in adults.
The Pharmaceutical Benefits Advisory Committee has also recommended Epclusa for listing on the PBS, with the medication currently the first and only pangenotypic single tablet regimen for a single treatment time of 12 weeks for the treatment of HCV genotypes 1-6 for patients without cirrhosis, or with cirrhosis and in combination with ribavirin for patients with decompensated cirrhosis.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jan 17
